BiomX Inc. (PHGE)
0.64
0.02 (2.51%)
At close: Mar 03, 2025, 3:59 PM
0.64
0.17%
After-hours: Mar 03, 2025, 07:29 PM EST
No 1D chart data available
| Bid | 0.64 |
| Market Cap | 11.63M |
| Revenue (ttm) | -287.65 |
| Net Income (ttm) | -31.09K |
| EPS (ttm) | -3.26 |
| PE Ratio (ttm) | -0.2 |
| Forward PE | -0.31 |
| Analyst | Buy |
| Ask | 0.77 |
| Volume | 210,771 |
| Avg. Volume (20D) | 86,925 |
| Open | 0.67 |
| Previous Close | 0.62 |
| Day's Range | 0.64 - 0.76 |
| 52-Week Range | 0.48 - 8.55 |
| Beta | 1.27 |
About PHGE
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 13, 2019
Employees 58
Stock Exchange AMEX
Ticker Symbol PHGE
Website https://www.biomx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for PHGE stock is "Buy." The 12-month stock price forecast is $13.5, which is an increase of 2009.38% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
5 days ago
-14.03%
BiomX shares are trading lower after the company a...
Unlock content with
Pro Subscription
6 months ago
-11.41%
BiomX shares are trading lower following Q2 financial results. Additionally, the company announced a 1-for-10 reverse stock split effective August 26th.
